FASENRA Regulatory Postmarketing Surveillance in Korea

Trial Identifier: D3250R00043
Sponsor: AstraZeneca
NCTID:: NCT05091333
Start Date: March 2022
Primary Completion Date: January 2025
Study Completion Date: January 2025
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea, South Korea Busan, South Korea, South Korea
South Korea, South Korea Daegu, South Korea, South Korea
South Korea, South Korea Gangwon-do, South Korea, South Korea
South Korea, South Korea Gwangju, South Korea, South Korea
South Korea, South Korea Gyeonggi-do, South Korea, South Korea
South Korea, South Korea Jeonju, South Korea, South Korea
South Korea, South Korea Seoul, South Korea, South Korea
South Korea, South Korea Suwon-si, South Korea, South Korea
South Korea, South Korea Ulsan, South Korea, South Korea